Overview
Dilraj Grewal, MD is a tenured Professor of Ophthalmology at the Duke Eye Center and serves as the Associate Director of the Duke Reading Center, a comprehensive image reading center that is a leader in analysis of ophthalmic images in multi-center clinical trials. He specializes in the medical and surgical management of patients with complex Vitreoretinal pathology and Uveitis. He joined the Duke Eye Center following completion of his Vitreoretinal Surgery fellowship at Duke and Uveitis fellowship training at Moorfields Eye Hospital in London. Dr. Grewal is focused on treating patients with new diagnostic and therapeutic modalities available as well as investigating several others in the pipeline to better help patients with these potentially blinding diseases.
He has been the recipient of numerous prestigious awards including the Ronald G. Michels Foundation Fellowship Award, the Heed Ophthalmic Foundation Fellowship Award, Senior Achievement Award from the American Academy of Ophthalmology and Rhett Buckler and Presidential Awards from American Society of Retina Specialists. He is an elected member of Retina Society, Clubs Jules Gonin and serves on the executive committee of the Macula Society.
Dr. Grewal has authored over 250 publications in peer-reviewed medical journals and over 300 presentations at national and international meetings. His research interests span assessment of retinal changes in neurodegenerative diseases, clinical research activities in advanced ocular imaging, surgical techniques and clinical trials for both Retina and Uveitis.
Current Appointments & Affiliations
Recent Publications
Immunoglobulin G4-Related Disease Manifesting as Posterior Uveitis.
Journal Article J Vitreoretin Dis · March 31, 2026 Purpose: To describe an atypical presentation of immunoglobulin G4 (IgG4)-related disease manifesting as posterior uveitis and masquerading as intraocular lymphoma. Methods: A single case was reviewed. Results: A 74-year-old man with a history of a left or ... Full text Link to item CiteAflibercept 2 mg Biosimilar (aflibercept-ayyh, Pavblu): Experience of safety in clinical settings-APEX- safety study.
Journal Article Eye (Lond) · March 2, 2026 Full text Link to item CiteRETINAL DIAGNOSTICS IN ALZHEIMER DISEASE: WHERE ARE WE NOW?
Journal Article Retina Today · March 1, 2026 Here’s how imaging is helping pave the path forward. ... CiteRecent Grants
A Phase IIb, Randomized, Assessor-Masked, Multicenter Clinical Trial To Assess The Safety And Efficacy Of Subretinal Implantation Of The CPCB-RPE1 Implant In Subjects With Advanced, Dry Age-Related Macular Degeneration (Geographic Atrophy)-PATCH AMD
ResearchPrincipal Investigator · Awarded by Clinical Trials Resource Group, LLC · 2024 - 2031A Phase 3 Randomized, Double-Masked, Placebo-Controlled Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults with Active, Non-Infectious Intermediate-, Posterior-, and Panuveitis
Clinical TrialPrincipal Investigator · Awarded by Priovant Therapeutics, Inc · 2024 - 2029A Phase 1/2a study of subretinal administration of OpCT-001 photoreceptor precursor cells derived from iPSCs in patients with primary photoreceptor disease
ResearchPrincipal Investigator · Awarded by BlueRock Therapeutics LP · 2025 - 2029View All Grants